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Prostate cancer (PCa) is driven by the androgen receptor (AR)-signaling
axis. Hormonal therapy often mitigates PCa progression, but a notable
number of cases progress to castration-resistant PCa (CRPC). CRPC
retains AR activity and is incurable. Long noncoding RNA (lncRNA) rep-
resent an uncharted region of the transcriptome. Several lncRNA have
been recently described to mediate oncogenic functions, suggesting that
these molecules can be potential therapeutic targets. Here, we identified
CRPC-associated lncRNA by analyzing patient-derived xenografts (PDXs)
and clinical data. Subsequently, we characterized one of the CRPC-pro-
moting lncRNA, HORAS5, in vitro and in vivo. We demonstrated that
HORAS5 is a stable, cytoplasmic lncRNA that promotes CRPC prolifera-
tion and survival by maintaining AR activity under androgen-depleted con-
ditions. Most strikingly, knockdown of HORAS5 causes a significant
reduction in the expression of AR itself and oncogenic AR targets such as
KIAA0101. Elevated expression of HORAS5 is also associated with worse
clinical outcomes in patients. Our results from HORAS5 inhibition in
in vivo models further confirm that HORAS5 is a viable therapeutic target
for CRPC. Thus, we posit that HORAS5 is a novel, targetable mediator of
CRPC through its essential role in the maintenance of oncogenic AR activ-
ity. Overall, this study adds to our mechanistic understanding of how
lncRNA function in cancer progression.
Abbreviations
AR, androgen receptor; CRPC, castration-resistant prostate cancer; DHT, dihydrotestosterone; HORAS, hormone resistance associated non-
coding sequences; HOTAIR, homeobox transcript antisense RNA; KIAA0101, PCNA clamp-associated factor; LincRNA, long intergenic
noncoding RNA; LncRNA, long noncoding RNA; LOC283070, uncharacterized long noncoding RNA; LTL, living tumor laboratory; Mir-645,
miRNA 645; NOD/SCID, nonobese diabetic/severe combined immunodeficiency; ORF, open reading frame; PCa, prostate cancer; PCAT4,
prostate cancer-associated transcript 4; PDX, patient-derived xenograft; PSA, prostate-specific antigen; qPCR, quantitative PCR; siRNA,
small-interference RNA; STMN1, stathmin.
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1. Introduction
Prostate cancer (PCa) proliferation is fueled by activa-
tion of the androgen receptor (AR)-signaling pathway
(Culig and Santer, 2014). Androgens directly bind to
the AR and trigger this process. Thus, hormone-depri-
vation therapy (aka surgical or medical ‘castration’) is
an effective therapeutic strategy for localized and
metastatic PCa. Unfortunately, a substantial fraction
of prostatic neoplasms (~ 25%) develop resistance to
castration, mainly via genetic and/or epigenetic alter-
ations that enable aberrant ligand-independent activa-
tion of AR-signaling (Feldman and Feldman, 2001;
Scher and Sawyers, 2005) and cell survival pathways
(Gao et al., 2013; Karantanos et al., 2013). Despite
the development of new therapies that delay disease
progression, castration-resistant PCa (CRPC) is still an
incurable disease (Chandrasekar et al., 2015). There-
fore, identification of alternative therapeutic targets is
of paramount importance.
Long noncoding RNA (lncRNA) are non-protein-cod-
ing transcripts longer than 200 nucleotides. The human
genome encodes for more than 50 000 unique lncRNA,
most of which are uncharacterized (Iyer et al., 2015). In
addition to their physiological roles (Li and Chang, 2014),
lncRNA are involved in pathological states including can-
cer (Huarte, 2015; Jariwala and Sarkar, 2016). For these
reasons, lncRNA have been proposed as a ‘gold mine’ for
the discovery of therapeutic targets in oncology. We
recently identified prostate cancer-associated transcript 18,
a lncRNA that drives androgen-dependent PCa prolifera-
tion and metastasis (Crea et al., 2014) and myocardial
infarction-associated transcript, a neuroendocrine PCa-
specific lncRNA (Crea et al., 2016). LncRNA have been
also implicated in PCa drug sensitivity (Malek et al., 2014),
metastatic progression (Shen et al., 2015), and prognosis
(Lee et al., 2014). Despite these developments, the role of
lncRNA in hormonal therapy resistance has not been
investigated systematically.
Patient-derived PCa tissue xenografts (PDXs) have
been very useful for translational cancer research
(Hidalgo et al., 2014). Unlike oligoclonal cell line
xenografts, PDXs more closely resemble the complex
cellular heterogeneity of human PCa (Siolas and Han-
non, 2013). We have developed a unique procedure for
grafting and serially transplanting primary human can-
cer tissues in nonobese diabetic/severe combined
immunodeficiency (NOD/SCID) mice, using the subre-
nal capsule graft site (Lin et al., 2014b). These trans-
plantable PDXs accurately recapitulate donor patient’s
tissue histology, genetic/epigenetic features, and drug
sensitivity (Lin et al., 2014a). We have successfully
applied PDXs for drug efficacy studies, discovery and
validation of therapeutic targets, and personalized can-
cer therapy (Lin et al., 2014a).
Using this technique, we have recently developed
pairs of PDXs with opposite sensitivity to castration
(Lin et al., 2014a). Here, we profiled three of these pairs
to identify lncRNA specifically up-regulated in meta-
static CRPC. Our results indicate that at least one of
these previously uncharacterized transcripts activates
pro-survival pathways and is functionally relevant in
the progression of PCa to a castration-resistant state.
2. Materials and methods
2.1. Cell culture
Human PCa cell lines were purchased from the Ameri-
can Type Culture Collection (ATCC, Burlington, ON,
Canada). Cells were cultured in RPMI-1640 media
(Gibco, Burlington, ON, Canada, Cat# 11875-093) sup-
plemented with 10% FBS (Gibco, Cat# 10099-141) and
following ATCC protocols for culture passage and stor-
age of cells (ATCC, cryogenic storage of animal cells
protocol). A humidified 37 °C 5% CO2 incubator was
employed for all culturing. Genetic fingerprinting and
monthly Mycoplasma tests were conducted at the Van-
couver Prostate Centre. Unless otherwise stated, all cells
were counted for experiments using a TC20 automated
cell counter (Bio-Rad, Mississauga, ON, Canada, Cat#
1450102) following manufacturer’s protocol (TC20
automated cell counter quick guide) and were
maintained until a passage of 20 or lower.
2.2. Patient-derived PCa xenograft
For generation of PDX models, primary tumor biopsies
were collected at the BC Cancer Agency or the Vancou-
ver Prostate Centre with patients’ written consent. All
surgical procedures and protocols for the acquisition
and research-wise handling of tumor biopsies were
approved by The University of British Columbia (UBC)
—Research Ethics Board (protocol#: H04-60131). PDX
was maintained by transplantation into subrenal cap-
sules of male NOD-SCIDmice obtained from the British
Columbia Cancer Research Centre—Animal Resource
Centre (Vancouver, Canada), as previously described
(Lin et al., 2014a). All animal experiments were per-
formed following the ethical guidelines and standards set
by the Declaration of Helsinki and in accordance with
the established animal care and use protocols approved
by the UBC Animal Care Committee (protocol #: A10-
0100).
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2.3. RNA extraction, reverse-transcription, and
quantitative PCR (qPCR)
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Toronto, ON, Canada) from cultured cells or
tissues following manufacturer’s protocol. Upon
extraction, 1000 ng of total RNA was reverse-tran-
scribed using the QuantiTect kit (Qiagen) following
manufacturer’s protocol. Reverse-transcription, geno-
mic DNA digestion was performed prior to cDNA
synthesis following manufacturer’s instructions. Pre-
designed or custom TaqMan primers (Life Technolo-
gies, Burlington, ON, Canada, Assay IDs for all
probes listed in Table S6) were used for quantitative
PCR (qPCR) to assess gene expression as per manu-
facturer’s protocol. Subcellular RNA fractionation was
performed using the Paris kit (Ambion, Life Technolo-
gies) following the manufacturer’s protocol and per-
forming the optional nuclear pellet washing step to
obtain purer fractions.
2.4. siRNA-mediated gene knockdown
Gene knockdown was performed using the reverse
transfection method (Hattori et al., 2017). Cells were
seeded in a six-well or 96-well plate along with the
lipid:small-interference RNA (siRNA) mixtures pre-
pared using the RNAiMAX (Invitrogen, Burlington,
ON, Canada) reagent as per the manufacturer’s
protocol. Final siRNA treatment dosages were 2 nM, and
all duplexes were purchased from IDT: HORAS5
(aka Linc00161, anti-HORAS5 DsiRNA 1: 50-GUGAU
AAUAAUAUAAACUACAGUCA-30, anti-HORAS5
DsiRNA 2: 50-CUAUGACUGUGGUAAACAUUUC-
CAA-30), PCNA clamp- associated factor (KIAA0101;
anti-KIAA0101 DsiRNA 1: 50-GUUUACCCUGGUAU
UCUAGAAUGTA-30, anti-KIAA0101 DsiRNA 2: 50-
AGUGUCUAGUUCUUGCUAAAAUCAA-30), and
nontargeting negative control, Cat#: 123762010. After 48
or 72 h post-transfection, treated cells were harvested for
extracting total RNAand/or total protein.
2.5. Cell proliferation and caspase activity assays
For both LNCaP and C4-2, 2000 viable cells were
seeded in a 96-well plate and reverse transfected with
either 2 nM of control siRNA or siRNA targeting the
HORAS5 transcript with six replicates for each treat-
ment. At days 1, 3, 5, and 7 post-transfection, cell via-
bility was assessed using the colorimetric CellTiter 96
Aqueous One Solution Cell Proliferation Assay (Pro-
mega, Madison, WI, USA, Cat# G3582) according to
the manufacturer’s protocol. Wells were incubated at
37 °C in a 5% CO2 incubator for 1.5 h prior to absor-
bance measurements using a spectrophotometer set to
490 nm. Values were plotted for each treatment after
normalizing to the NC Day 1 average reading.
2.5.1. DHT-rescue experiment
A total of 2000 viable LNCaP cells per well were pla-
ted in a 96-well plate and reverse transfected with
HORAS5-targeted or control siRNA (2 nM dosage) as
described above. Cells were then daily supplemented
with either 10 nM dihydrotestosterone (DHT) or etha-
nol (vehicle control), and viability was calculated using
the MTS assay and described above.
2.5.2. Caspase activity assays
Cells were plated in a white, flat-bottom 96-well plate
and treated with siRNA as described with 6 replicates
for each treatment. At day 3 post-transfection, Cas-
pase-Glo reagent (Promega) was added to cells and
total luminescence was quantified following manufac-
turer’s protocol. These luminescence values were nor-
malized to time-match and treatment-matched cell
viabilities for each group and were plotted relative to
the control siRNA-treated samples.
2.6. RNA half-life measurement
A total of 100 000 cells were plated in a six-well and
treated with 50 lgmL1 of alpha-amanitin (Sigma,
Oakville, ON, Canada, A2263), as described (Khalil
et al., 2008). Total RNA was extracted at time-points
0, 2, 5, 6, and 10 h postincubation, and gene expres-
sion was analyzed by qPCR as previously described.
2.7. Cell cycle analysis
Cell cycle phase estimates were obtained using fluores-
cence-activated cell sorting flow cytometry. First,
LNCaP and C4-2 cells were treated with a scramble
control duplex or targeted anti-HORAS5 DsiRNA for
72 h. A total of 4.0 9 105 cells were then harvested
post-treatment, including untreated and lipofectamine
RNAiMAX controls, and resuspended in 100 lL of
ice-cold DPBS (Gibco, Cat# 14190144). Next, 900 lL
of ice-cold 70% ethanol was added dropwise while
vortexing cells to prevent aggregates from forming.
Cells were left in 15-mL falcon tubes at 4 °C for
1 week for fixation. The following week, the ethanol
was removed by centrifugation and cells were washed
with DPBS once. Cell cycle phase was determined
using propidium iodide (PI) staining buffer of
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composition 0.1% Triton X-100, 100 lgmL1 RNase
(Invitrogen, Cat# 12091039), and 10 lgmL1 of PI
(Sigma, Cat# P4170). After 30 min in the dark with
the PI stain, cells were analyzed by FACScalibur (Bec-
ton Dickenson, Mississauga, ON, Canada) and were
gated first by side scatter vs forward scatter, and then
by FL2-Area vs FL2-Width. Counts were then plotted
against FL2-Area for selection of G1, S, and G2/M
phases. Phasing estimation was obtained using FLOWJO
v10 software (FlowJo, Ashland, OR, USA). A total of
20 000 cells were analyzed to get representative counts
per phase. Significance was determined by comparing
the NC to treated cells in each phase (Student’s t-test).
‘Cell cycle phase’ represents either a single (G1) or
double (S/G2-M) complement of DNA.
2.8. Western blotting analysis
Cell lysates were created using 100 lL of RIPA buffer
unless otherwise stated. Proteins (50 lg) were resolved
via gel electrophoresis on reducing SDS/PAGE run at
100V for 1 h. Transfer to nitrocellulose membranes was
done at 100V for 1 h as well. The membranes were
blocked in 5% skim milk dissolved in TBS-T wash buffer
(Tris-buffered saline containing 0.1% Tween) at room
temperature for 1 h. Following this, blots were incu-
bated overnight at 4 °C with protein-specific primary
antibodies containing 5% BSA to b-actin at 1 : 5000
(Sigma, Cat# A5441), KIAA0101 at 1 : 1000 (Abnova,
Burlington, ON, Canada, Cat# H00009768-M01), and
AR Primary Ab (Santa Cruz, Mississauga, ON, Canada,
Cat# sc-7305) 1 : 500 in TBS-T + 5% BSA. After incu-
bation, blots were washed four times in TBS-T for 5 min
each. Lastly, blots were incubated with HRP-conjugated
anti-mouse secondary antibody diluted in 10 mL of
TBS-T at room temperature for 1 h (b-actin 1 : 5000,
KIAA0101 1 : 1000, and AR 1 : 2000). After washing as
above, chemiluminescence was determined in a GelDoc
system using an ECL western blotting substrate kit
(ThermoFisher, Burlington, ON, Canada Cat# 32016).
2.9. In vivo gene knockdown
Gene knockdown in vivo was achieved using the Atelo-
Gene in vivo siRNA/miRNA Transfection kit
(REPROCELL, Beltsville, MD, USA) following manu-
facturer’s protocol. Castrate-resistant LNCaP cells were
xenografted in both dorsal flanks of intact male,
immunocompromised NOD/SCID mice as previously
described (Kuruma et al., 2013) and were randomly
assigned to each treatment group (n = 3, i.e., six
tumors/treatment). Two nanomolar total dosage of
HORAS5 siRNA was locally injected to surround the
tumor as per manufacturer’s protocol for two consecu-
tive days. Tumors were harvested 3 days after the first
injection to assess tumor volume and target knock-
down. All animal experiments were performed follow-
ing the ethical guidelines and standards set by the
Declaration of Helsinki and in accordance with the
established animal care and use protocols approved by
the UBC Animal Care Committee (protocol #: A10-
0100). Total RNA was extracted as described above,
and genes were quantified using RT-qPCR to assess
knockdown efficiency.
2.10. Wound-healing (migration) assays
For LNCaP and C4-2 cell lines, 18 h post-transfection with
either NC duplex or anti-HORAS5 siRNA. 2.0 9 106 cells
per six well for LNCaP cells, and 3.5 9 106 cells per 60-
mmdish for C4-2 cells were seeded. Only six wells were pre-
coated with poly-L-lysine for 3 h (Sigma, Cat# P4707) and
rinsed with dH2O. Both LNCaP and C4-2 cells were left to
adhere for 4–5 h before scratching the wells using a sterile
P10 micropipette tip. Assays used serum-free media to pre-
vent cell growth. Twenty-four hours postscratch, cells were
visualized and captured using an AxioCamMRc real-time
camera (Zeiss, Toronto, ON, Canada).Wound closure was
quantified using Adobe Photoshop as described (Chiang
et al., 2014).
2.11. Boyden chamber (invasion) assays
LNCaP and C4-2 cells were first either left untreated,
or were transfected with NC duplex or anti-HORAS5
siRNA for 18 h in 60-mm dishes. Next, cell invasive
potential was examined using polyethylene terephtha-
late-coated 24-well transwell chambers with a pore size
of 8 lm (Corning, Corning, NY, USA, Cat# 354480).
Prior to the assay, top and bottom chambers were re-
hydrated using 500 lL of prewarmed serum-free
media for 2 h at 37 °C. Following this, 1.0 9 105 cells
were seeded per well in serum-free media, and the
assay was carried out according to manufacturer’s
protocol. Media supplemented with 10% FBS was
used as a chemoattractant in the bottom of each well.
Cells were incubated for 48 h prior to quantification
using cell dissociation solution (Trevigen, Gaithers-
burg, MD, USA, Cat# 3455-096-05) diluted in
MQH2O and Calcein AM (Trevigen, Cat# 4892-010-
01). Once mixed, 300 lL of complete dissociation
solution was added to the bottom chambers for 1 h.
One hundred microliter of dissociated cells was used
for 96-well plate quantification using an excitation
and emission of 485 and 520 nm, respectively. All
readings were done in duplicate.
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2.12. Immunohistochemical staining
In vivo treated tumors from all groups were used to
generate tissue microarray and stained for cleaved Cas-
pase 3 using a rabbit monoclonal antibody at 1 : 50
dilution (Cell Signaling, Whitby, ON, Canada, Cat#
9664). Tissue sections were divided into nine quadrants
prior to counting. Five of the total nine quadrants
were used to take positively stained cell counts, which
were then compared to total cells in the visual field.
All five field counts were averaged and converted to a
percentage value for control and treatment.
2.13. RNA sequencing and differential expression
analysis
Total RNA was used to generate the sequencing
library as previously described (Lin et al., 2014a).
Briefly, RNA sequencing fastq files were processed to
read counts using the STAR short read aligner
(https://github.com/alexdobin/STAR) with an index
built with the hg19 genome GENCODE v19 transcrip-
tome reference, and the -quantMode option. Genes
with 0 counts in both libraries were eliminated.
Twenty-five (25) was added to the read count for each
gene to handle genes with 0 reads in one library and
normalized per million mapped reads (RPKM) in each
library. Genes were then filtered for ‘lincRNA’ type
and sorted in descending order of up-regulation in the
CRPC [living tumor laboratory (LTL)-313BR] sample.
To identify the up- and down-regulated lincRNA,
fold-change (FC) cutoff of three was used and
lincRNA were ranked in order of FC for hormone
resistance associated non-coding sequences (HORAS)
annotation.
2.14. Proteomics analysis
A total of 10 million viable LNCaP cells were plated
in a T150 flask and treated with either control or anti-
HORAS5 as described earlier. At 3 days after treat-
ment, cells were washed once with ice-cold 19 PBS
and snap-frozen to perform the proteomics analysis at
the UBC Proteomics Core Facility at the Centre for
High-Throughput Biology (Vancouver, Canada).
Briefly, protein extracts from treated cells were sus-
pended in SDS sample buffer and run on a short 10%
SDS/PAGE gel. Proteins were visualized by colloidal
coomassie (Candiano et al., 2004) and digested out of
the gel as described (Chan et al., 2006). Peptide sam-
ples were purified by solid phase extraction on C-18
stop and go extraction (STAGE) Tips (Ishihama et al.,
2002), and each treatment was labeled by reductive
dimethylation using formaldehyde isotopologues (Par-
ker et al., 2012). The final product was purified again
by C18 STAGE tips as previously done and analyzed
by LC-MSMS (Kang et al., 2014). Protein identifica-
tion and quantification were performed with MAX-
QUANT v1.5.1.0 as described (Cox et al., 2009).
2.15. In silico miRNA binding prediction analyses
In order to predict miRNA that could be interacting
with HORAS5, we used an online transcriptome-wide
miRNA binding prediction tool (http://www.mircode.
org/index.php) from the Larsson Lekholm Lab from
the Institute of Biomedicine, University of Gothenburg
(http://larssonlab.org/). The tool was run using default
parameters, and the entire output data have been sum-
marized in a table in Fig. S12. Additional information
about this prediction software is available on the lab’s
website.
2.16. Availability of data and materials
All data generated or analyzed during this study are
included in this published article (and its supplemen-
tary information files).
3. Results
3.1. Identification of hormone therapy resistance-
associated lincRNA
To identify lncRNA that are up-regulated upon pro-
gression of primary PCa to CRPC, we analyzed our
unique collection of PCa PDX models (Lin et al.,
2014a). These PDXs were grown in the subrenal cap-
sule of immunocompromised male mice. PDX-bearing
mice were surgically castrated at about 10–12 weeks
postengraftment (black arrowheads, Fig. 1A). As
expected, castration resulted in a dramatic reduction
of plasma prostate-specific antigen (PSA) levels, which
is a canonical AR target gene and strongly correlated
with the total tumor burden (Figs 1A and S1A). Anal-
ogous to the clinical progression of some PCas, in
three PDX models the tumors eventually relapsed after
about 20 weeks to produce a castration-resistant
subline. The relapsed, castration-resistant tumors dis-
played signs of AR-signaling re-activation, as evi-
denced by the parallel increase in plasma PSA levels
(Figs 1A and S1A). Of these PDX models, we chose
the most well-established and previously described
LTL-313B/BR pair for a comprehensive RNA sequen-
cing analysis (Luk et al., 2017). Notably, the relapsed
castration-resistant LTL-313BR subline retains AR
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expression and is markedly resistant to clinical AR-
antagonistic drugs bicalutamide and enzalutamide
relative to the parental subline (Luk et al., 2017). This
implies that a broad spectrum of molecular mecha-
nisms that regulate CRPC growth underlies the sur-
vival and proliferation of LTL-313BR under castrate
conditions. To investigate this further, we decided to
focus on the intergenic subclass of lncRNA (here-
inafter referred to as lincRNA) that are coded on dis-
tinct chromosomal loci and thus are easier to
functionally characterize. Differential gene expression
analysis between LTL-313BR vs 313B revealed 57
lincRNA that were up-regulated (FC ≥ 3), and 329
lincRNA that were down-regulated (FC ≤ 3) in the
hormone therapy-resistant subline (Tables S1 and S2,
respectively). Consistent with previous studies, we
found PCa progression-associated PCAT4 (Prensner
et al., 2011) among the up-regulated transcripts, and
in vivo androgen-regulated prostate cancer-associated
transcript 9 (Parolia et al., 2015) among the down-
regulated lincRNA. Since a relevant portion of these
lincRNA were previously unannotated, we termed
them as HORAS. To confirm the RNA sequencing
results and to profile the expression of other
differentially expressed lincRNA in other PDX pairs,
we performed qPCR gene expression analyses. Our
results confirmed up-regulation of the selected HORAS
transcripts in LTL313BR vs LTL-313B, and in two
other PDX pairs (Fig. 1B–F). HORAS5 (aka
linc00161, NCRNA00161, C21orf100, linc-USP16) was
significantly up-regulated in all the three castration-
resistant PDXs (4–130-fold; Fig. 1B). Therefore, we
pursued HORAS5 for further functional characteriza-
tion in CRPC-derived PCa cells.
The Ensembl database categorizes HORAS5 as a
lincRNA gene and annotates it as linc00161 (aka
C21orf100, NCRNA00161) with two splice variants.
The open reading frame (ORF) finder database (http://
www.ncbi.nlm.nih.gov/gorf/gorf.html) confirmed that
at least 88% of this transcript does not contain an
ORF. Test code software (Fickett, 1982) confirmed
that the transcript is noncoding (P < 0.01). Interest-
ingly, HORAS5 was first described in a study pub-
lished over a decade ago which attempted to profile
novel genes encoded on chromosome 21 and could be
implicated in Down syndrome (Reymond et al., 2002).
At the time, the authors confirmed HORAS5 tran-
script structure via 50- and 30-end rapid amplification
Fig. 1. HORAS5 is up-regulated in CRPC. (A) PSA levels in three independent hormone-sensitive patient-derived xenografts in NOD-SCID
mice. Arrows represent androgen deprivation (via surgical castration) followed by relapse around 20–30 weeks. (B–F) qPCR expression of
HORAS5 (B, aka linc00161), HORAS1 (C, aka RP11-945A11.1), HORAS2 (D, aka AF131217.1), HORAS27 (E, aka PCAT4), HORAS20 (F, aka
AP001604.3) identified from differential expression analyses between hormone-sensitive (LTL313B) and relapsed (LTL313BR) PCa PDXs.
Results expressed as means  SD from two independent replicates. Student’s t-test was performed for statistical comparisons. *P < 0.05,
**P < 0.01, and ****P < 0.0001. HORAS1 was undetectable in the remaining samples.
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of cDNA ends. Additionally, the same study showed
via qPCR that HORAS5 was robustly expressed only
in normal prostate tissue compared to 20 other normal
tissue types (Reymond et al., 2002). This prostate-spe-
cific expression was corroborated by an independent
study using an array-based transcriptomic technique in
a panel of 12 normal tissues (Fig. S2A). Concordantly,
we found HORAS5 to show the highest expression in
PCa specimens across all TCGA-sequenced cancers
(Fig. S2B). Of note, a recent study reported that
HORAS5 was induced by chemotherapy in
osteosarcoma cells (Wang et al., 2016b). However, no
functional knowledge exists on the biological role of
HORAS5 in PCa pathogenesis.
As a first step, we profiled the expression of
HORAS5 in a panel of PCa cell lines. We found that
HORAS5 was considerably expressed only in AR-posi-
tive CRPC-derived cell lines (Sedelaar and Isaacs,
2009; Thalmann et al., 1994), and was undetectable in
non-neoplastic BPH cells (Fig. 2A). Our data also
indicated that the longer HORAS5 transcript variant
was much more abundant than the shorter one in most
Fig. 2. HORAS5 is a stable cytoplasmic lncRNA in AR-positive PCa cells. (A) Basal expression (qPCR) of HORAS5 in a panel of PCa cell
lines. Gene expression was normalized to average of GAPDH and HPRT1 and shown relative to BPH1. (B) Taqman qPCR expression of
HORAS5 long and short variants (as identified in the Ensembl database) in two CRPC-derived cell lines, namely LNCaP and C4-2. (C) qPCR
expression of HORAS5 in the nuclear and cytoplasmic subcellular fractions of AR-positive LNCaP cells. GAPDH and snoRNA55 are used as
controls for cytoplasmic and nuclear fractions, respectively. Results from two independent experiments are plotted. (D) qPCR-based
transcript expression of HORAS5 and c-Myc in LNCaP cells treated with alpha-amanitin for various time-points (0, 2, 5, 6, 10 h post-
treatment). Relatively stable GAPDH expression was used for normalization, and data are plotted relative expression at 0 h. Results from
two independent experiments are plotted as means  SD.
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PCa cells and PDX models (Figs 2B and S3A,B),
prompting us to functionally pursue the longer variant
(hereafter referred to as HORAS5 alone). This
restricted in vitro expression of HORAS5 in AR-posi-
tive CRPC cell lines is consistent with the in vivo
expression profile observed in our AR-positive
CRPC-derived PDX models.
Next, subcellular RNA fractionation experiments
revealed that HORAS5 was predominantly localized in
the cytoplasm of the cell (Figs 2C and S3C). Since
lincRNA, unlike a protein-coding mRNA, are end
functional entities, we investigated the stability of the
HORAS5 transcript itself. To this end, we treated
LNCaP cells with a-amanitin, a potent inhibitor of
RNA polymerase II, and thereafter measured the rela-
tive RNA abundance at various time-points (qPCR).
Compared to the mRNA of a known oncogenic factor,
c-Myc, HORAS5 possessed a longer half-life of about
3 h (Fig. 2D). This implies that HORAS5 is relatively
stable inside cells for several hours post-transcription,
thereby allowing it to mediate important cellular func-
tions.
3.2. Functional characterization of HORAS5
So far, we have shown that among the differentially
expressed lincRNA, HORAS5 is the most consistently
up-regulated gene in hormone therapy-resistant PCa
and is predominantly retained in the cell cytoplasm.
To investigate the biological function of HORAS5, we
used two distinct siRNA to knockdown this gene in
LNCaP and C4-2 cells, both capable of growing
under castrate levels of testosterone, and both
expressing a mutated AR gene (Sedelaar and Isaacs,
2009; Walker et al., 2014). With both the siRNA
duplexes, we were able to achieve a robust and con-
sistent knockdown with > 80% efficacy at a dosage as
low as 2 nM (Figs 3A,B and S4). Notably, HORAS5
Fig. 3. HORAS5 knockdown attenuates cell proliferation in vitro. (A, B) qPCR expression levels of HORAS5 in LNCaP (A) and C4-2 (B) cells
upon treatment with nontargeting control siRNA (NC) or two distinct anti-HORAS5 siRNA (2 nM dosage). Data shown are a single
representative trial. (C, D) MTS cell proliferation assays for LNCaP (C) and C4-2 (D) upon treatment with anti-HORAS5 siRNA or controls
siRNA. Two-way ANOVA with multiple comparisons (Tukey’s post t-test) performed to measure significance, ****P < 0.0001. Results are
from three independent experiments.
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knockdown significantly attenuated the growth of
both LNCaP and C4-2 cells grown in castrate levels
of testosterone (Fig. 3C,D, respectively). Consistently,
cell cycle analyses revealed a modest, yet significant,
decrease in the fraction of cells entering the S-phase
after HORAS5 knockdown relative to control siRNA
treatment, with a parallel increase in the G0/G1 frac-
tion (Fig. S5A,B). In accordance with the previous,
induction of apoptotic caspase enzymes was observed
upon treatment with both anti-HORAS5 siRNA
(Fig. 4A–C). However, we did not observe a marked
attenuation in invasion or migration potential upon
siRNA-mediated knockdown of HORAS5 at nontoxic
doses (Figs S6 and S7). Together, these data strongly
implicate HORAS5 in the survival and proliferation
of CRPC-derived PCa cells.
Since HORAS5 was up-regulated in CRPC tumors,
we questioned if its biological relevance in PCa was
restricted only to castrate conditions. LNCaP cells
represent an ideal model to test this hypothesis
because they were derived from a castration-resistant
PCa, but physiologic levels of testosterone further
stimulate their proliferation (Alisky et al., 2010). To
this end, we knocked down HORAS5 in LNCaP cells
either in the absence or presence of DHT, a potent
physiological AR agonist. Addition of DHT markedly
rescued cell death observed upon HORAS5 knock-
down using both siRNA (Fig. 4D). This indicates that
HORAS5 plays a pro-survival role primarily under
castrate levels of androgen, suggesting there may be a
functional association of HORAS5 with the AR path-
way.
Fig. 4. HORAS5 knockdown induces caspase-mediated apoptosis in vitro. (A–C) Caspase 3/7 (A), Caspase 8 (B), and Caspase 9 (C)
activities normalized to relative LNCaP cell number 3 days post-transfection of HORAS5-siRNA vs nontargeting control siRNA. One-way
ANOVA with Tukey’s posttest, ****P < 0.0001. Results are expressed as means  SD from two independent replicates. (D) Relative viable
cell counts of LNCaP cells upon knockdown of HORAS5 (48 h) with or without DHT supplementation. Results are expressed as
means  SD from two independent replicates. Student’s t-test performed for statistical comparisons with ****P < 0.0001.
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3.3. Mechanisms of HORAS5-dependent PCa cell
survival
Our results so far indicate that HORAS5 plays a key
role in CRPC survival and growth. We next set out to
investigate the molecular correlates of HORAS5-
dependent PCa progression. The majority of the func-
tional studies to date have revealed that lncRNA fold
into three-dimensional structures and interact with a
wide range of protein partners, thereby regulating their
function (Cao et al., 2015). Thus, to explore the mech-
anisms underlying the oncogenic functions of
HORAS5, we adopted an unbiased proteomics
approach (Fig. S8).
We first knocked down HORAS5 in LNCaP cells
using two distinct siRNA and a control nontargeting
siRNA. We then performed quantitative, tandem mass
spectrometry proteomic analyses using treated cell
lysates. Differential protein abundance analysis
revealed 224 proteins that were significantly increased
and 34 that were significantly decreased by greater
than threefold in HORAS5-knockdown cells relative to
the control (Tables S3 and S4, respectively). Next, we
conducted an Oncomine-based pathway analysis of the
genes that were significantly down-regulated upon
HORAS5 silencing. The most significantly associated
concept was ‘RNA polymerase II-transcription factor
activity’ (Table S5). Since AR-RNA Polymerase II
complexes have been identified as the main drivers of
PCa (Wang et al., 2007), we decided to investigate
whether the antiproliferative effect of HORAS5 silenc-
ing was at least in part mediated by inhibition of the
AR transcriptional program.
Strikingly, upon HORAS5 knockdown, several
canonical AR targets were markedly down-regulated
(> 50%, Fig. 5A), including PSA (aka KLK3) and
NKX3.1. Beyond canonical targets, a literature search
revealed that several other genes that were down-regu-
lated upon HORAS5 knockdown were also activated by
AR. For instance, the second most down-regulated pro-
tein, KIAA0101 (> 5-fold), was recently confirmed as
an AR-activated gene in a study using patient specimens
Fig. 5. HORAS5 regulates the expression of AR target genes and has prognostic value in PCa. (A) mRNA expression of the labeled genes
after siRNA-mediated knockdown of HORAS5 in LNCaP cells. (B) Relative mRNA expression (qPCR) of KIAA0101 post-HORAS5 knockdown
in LNCaP and C4-2 cells. (C) Relative mRNA expression (qPCR) of AR post-HORAS5 knockdown in LNCaP and C4-2 cells. (D) MTS cell
proliferation assay in C4-2 cells upon treatment with anti-KIAA0101 siRNA (2 nM dose) or a control siRNA (5 nM dose). (E) Relative
expression (qPCR) of AR mRNA in LNCaP treated with either HORAS5-targeting or control siRNA (5 nM for 24 h), followed by treatment
with the transcriptional inhibitor Actinomycin-D (20 lM) for increasing durations. (F) postprostatectomy disease-free survival based on
HORAS5 expression [cBioportal, TCGA PCa database, 456 vs 35 (Elevated HORAS5) patients]. All qPCR results shown as data from at least
two independent replicates, statistical analyses using one-way ANOVA with Tukey’s post-test, ****P < 0.0001.
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(Shaw et al., 2016). KIAA0101 has been described as a
potent oncogene in many cancers (Hosokawa et al.,
2007; Zhu et al., 2013) and has been categorized as an
anaphase promoting protein (Emanuele et al., 2011).
No study to date has described the biological functions
of KIAA0101 in PCa. Thus, we set out to further explore
any cellular interplay betweenHORAS5 and KIAA0101.
In CRPC C4-2 cells, HORAS5 knockdown led to a sig-
nificant reduction in the KIAA0101 mRNA levels by
> 60% (Fig. 5B). This reduction in KIAA0101 mRNA
translated to a significant reduction of KIAA0101 pro-
tein (Fig. S9D), also verifying our initial proteomics
analyses. To explore this further, we knocked down
KIAA0101 in CRPC-derived C4-2 cells using two dis-
tinct siRNA (Fig. S9A,B). KIAA0101 silencing alone
significantly inhibited the growth of C4-2 cells
(Fig. 5D), suggesting that the antiproliferative effect of
HORAS5 inhibition can be partly explained by down-
stream reduction in oncogenic AR targets like
KIAA0101. Our proteomic data were further validated
by qPCR analysis of another down-regulated gene in
HORAS5 silenced samples, called stathmin (STMN1;
Fig. S10A). Notably, STMN1 is also an AR-regulated
gene (Yan et al., 2013) and has been previously associ-
ated with oncogenic features (Hemdan et al., 2014; Nie
et al., 2015). Thus, we found several AR target genes to
be markedly down-regulated upon HORAS5 knock-
down, which prompted us to query the expression of
AR itself. Remarkably, HORAS5 knockdown signifi-
cantly reduced AR expression at the transcript and pro-
tein level in both LNCaP and C4-2 cells (Figs 5C and
S10B); however, HORAS5 itself was not regulated by
AR activity (Fig. S10C). From a mechanistic stand-
point, we assessed the stability of the AR mRNA in
presence and absence of HORAS5. Here, we found that
HORAS5 knockdown reduced the stability of the AR
mRNA (Fig. 5E), but found no change in the stability
of the controlMYC and HPRT1 mRNA (Fig. S11A,B).
This strongly suggests that HORAS5 may be involved
in the post-transcriptional regulation of the AR. Consis-
tently, upon HORAS5 knockdown we found a signifi-
cant decrease in the mature AR mRNA, but found no
change in the abundance of the premature, intron-con-
taining AR transcript (Fig. S11C). Together, this evi-
dence, and the experimental data shown in Fig. 4D,
position HORAS5 as an androgen-independent tran-
script that is required for activation of the oncogenic
AR transcriptional program, through post-transcrip-
tional maintenance of AR mRNA stability.
Next, to clinically interpret the HORAS5-asso-
ciated protein signature, we individually uploaded
the differential expressed genes from the proteomics
analyses into the Oncomine database. Proteins that
were markedly reduced in response to HORAS5
knockdown strongly correlated with increased odds
of disease recurrence at 3 and 5 years after primary
treatment (Fig S8). Direct evaluation of HORAS5
expression in PCa patient samples also confirmed
that higher expression of this lincRNA predicted
poorer clinical outcome in terms of overall survival
(Fig. 5F). These clinical correlations are consistent
with HORAS5 mediating major proliferative func-
tions in PCa under hormone-depleted conditions as
shown above. The proteins that were up-regulated
upon HORAS5 knockdown returned no significant
association (P < 0.001) with any clinical variables.
Next, we queried the TCGA PCa transcriptomic
data to identify genes that have significant positive
correlation with HORAS5 expression. Using these
genes, we then performed a computational analyses,
called BART (Amaral et al., 2018), to predict the
common regulatory transcription factors. Consistent
with the involvement of HORAS5 in maintenance of
AR-signaling, BART analyses predicted AR to be
one of top regulatory factors for the HORAS5-asso-
ciated genes in patient tumors (Fig. S11D). As
expected, similar analyses for negatively correlated
genes did not return the AR as a significant tran-
scription factor (Fig. S11D).
3.4. Therapeutic potential of HORAS5
inactivation
Thus far, we have established that HORAS5 drives
CRPC growth by supporting oncogenic AR transcrip-
tional programs and cellular availability of several
oncogenic proteins. We then sought to validate the
oncogenic roles of HORAS5 in vivo. For this, we gen-
erated in vivo androgen-insensitive sublines of LNCaP
as previously described (Kuruma et al., 2013). Using
the AteloGene delivery system (Takeshita et al.,
2005), after 2 consecutive siRNA injections, we were
able to achieve a significant knockdown of HORAS5
by about 50% (Fig. 6A). This inhibition of HORAS5
expression ensued in a significant reduction in tumor
volume relative to the control (Fig. 6B). To confirm
whether this reduction was due to apoptotic killing of
tumor cells, we generated tissue microarrays from the
treated tumors and stained for active/cleaved Caspase
3. Complementing the reduction in tumor volume,
inhibition of HORAS5 led to significantly higher
staining for cleaved Caspase 3 in tumor cells (Fig. 6C,
D). These results indicate that HORAS5 modulates
CRPC cell proliferation and survival in vivo and that
it could be used as a novel therapeutic target for
CRPC.
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4. Discussion
In this study, we have identified HORAS5 as a media-
tor of CRPC cell proliferation and as a potential ther-
apeutic and prognostic target for PCa. Preclinical data
obtained using different cell lines indicate that
HORAS5 is required for CRPC cell survival in cas-
trate levels of testosterone. In keeping with this
hypothesis, we showed that HORAS5 is highly
expressed in early clinical PCa specimens and in CRPC
PDX. Additionally, higher HORAS5 expression in pri-
mary PCa samples predicts poorer clinical outcome.
Our results also indicate that HORAS5 is predomi-
nantly contained in the cytoplasm of PCa cells where
it regulates the stability of the AR mRNA. In
osteosarcoma cells, this lncRNA has been recently
shown to be associated with the AGO complex, where
it buffers miRNA 645 (mir-645) and indirectly
increases the levels of the pro-apoptotic interferon-
induced protein with tetratricopeptide repeats two pro-
tein (Wang et al., 2016b). However, our proteomic
(Tables S3 and S4) and miRNA binding prediction
data (Fig. S12A) did not show the existence of this
pathway in PCa cells, where the lncRNA seems to play
an oncogenic role. Moreover, mir-645 was not
expressed in AR-positive PCa cells (Fig. S12B).
Instead, our results are more in line with recent evi-
dence showing that HORAS5 overexpression is associ-
ated with worse prognosis in hepatocellular carcinoma
patients (Xu et al., 2017). The previous study also
showed that HORAS5 drives the metastatic potential
of liver cancer cells. Taken together, this evidence indi-
cates that the effects of HORAS5 expression are tissue-
and disease-specific, as described for other lncRNA
(Huarte, 2015; Schmitt and Chang, 2016).
In this study, we have shown using different tech-
niques that HORAS5 silencing leads to a marked inhi-
bition of the KIAA0101 oncogene. KIAA0101 has been
Fig. 6. HORAS5 knockdown attenuates tumor growth in vivo. (A) Relative expression of HORAS5 (qPCR) 72 h following AteloGene:siRNA
injections (n = 3 in each arm). Raw values were normalized to GAPDH and HPRT1 and shown relative to the control group (***P < 0.001).
(B) Quantitative measurements of tumor volume postknockdown of HORAS5 (72 h). Statistical significance from Student’s t-test with
*P < 0.05. (C) Representative IHC images for cleaved Caspase 3 from control siRNA (NC) and anti-HORAS5 siRNA treatment groups. The
scale bar at the bottom marks a 20 lm width. (D) Overall IHC staining quantification from C. Results are expressed as percent of positive
cells to total cells in the visual field. Data are shown as means  SD, and a Student’s t-test was used to calculate significance, *P < 0.05.
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described as a pro-survival oncogene in several cancer
types (Hosokawa et al., 2007; Zhu et al., 2013) and as
a driver of cell cycle progression (Emanuele et al.,
2011). Our data show that HORAS5 silencing attenu-
ates cell cycle progression and induces caspase-depen-
dent apoptosis in CRPC-derived cells. Interestingly,
HORAS5 silencing significantly attenuates the AR
transcriptional program, with marked reduction in
oncogenic AR targets such as KIAA0101. This can be
explained by the decrease in the expression of AR
mRNA itself likely due to reduced cytoplasmic stabil-
ity in absence of HORAS5. Several other oncogenic
proteins are positively associated with HORAS5
expression as well (Table S3). This suggests that target-
ing HORAS5 could simultaneously block multiple key
oncogenic pathways in CRPCs.
Other lncRNA have been previously identified as
potential drivers of CRPC. In particular, uncharacter-
ized long noncoding RNA (LOC283070) has been
shown to induce the proliferation of LNCaP cells in
androgen-depleted media (Wang et al., 2016a). Since
this lncRNA had not been described before, we
decided to analyze its expression in our models. Unfor-
tunately, we were unable to do so, since we found that
the primers used to measure LOC283070 expression
perfectly overlap with the CAMK1D protein, which
has been identified as a potential interactor of
LOC283070. In addition, the siRNA sequences used to
silence LOC283070 show a substantial overlap with
the CAMK1D protein. Based on these findings, we
question the assumption that LOC283070 is a true
lncRNA. On the contrary, homeobox transcript anti-
sense RNA (HOTAIR) is a well-characterized onco-
genic lncRNA, which is mainly expressed in the
nucleus and binds directly to the AR. A recent study
identified HOTAIR as a putative driver of CRPC pro-
gression (Zhang et al., 2015). Notably, this study did
not test the therapeutic potential of HOTAIR knock-
down in vivo. Hence, this manuscript reports the func-
tional characterization of a lncRNA that drives CRPC
in vitro and in vivo.
5. Conclusion
Our study indicates that the cytoplasmic lncRNA,
HORAS5, mediates CRPC progression in an AR-
dependent manner by regulating AR mRNA stability,
and is associated with poorer clinical outcome in
human PCa samples. In addition, our in vivo data fur-
ther implicate lncRNA as putative therapeutic targets
for CRPC (Fig. 6). Thus, our study adds to the
mounting evidence that centrally implicates lncRNA in
cancer biology, and warrants the development of
innovative therapies that target oncogenic noncoding
RNA molecules in advanced, lethal PCa.
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